[关键词]
[摘要]
干眼是全球广泛分布的多因素眼病,其病理生理核心在于先天与适应性免疫应答交互激活所驱动的慢性炎症循环。持续的炎症破坏泪膜稳态,并与泪液渗透压升高相互加剧,最终导致视功能下降和生活质量受损。文章以干眼的免疫病理机制为切入点,系统比较了环孢素A、立他司特与他克莫司三种代表性局部免疫调节剂的作用靶点、临床证据与安全性特征。这三种药物通过在不同环节阻断T细胞的活化与增殖,中断了炎症的自我扩增环路,目前已成为中重度干眼长期管理的核心方案。通过分析现有研究的局限性,文章指出未来应着力开展更多头对头临床试验、寻找可预测疗效的生物标志物,以弥补当前的证据缺口,为临床合理选择药物提供参考。
[Key word]
[Abstract]
Dry eye disease(DED)is a widespread, multifactorial ocular disorder. Its core pathophysiological mechanism involves a self-perpetuating cycle of chronic inflammation driven by the reciprocal activation of innate and adaptive immune responses. Persistent inflammation disrupts tear film homeostasis, which in turn exacerbates elevated tear osmolarity in a mutually reinforcing manner, ultimately leading to a decline in visual function and impaired quality of life. Focusing on the immunopathogenesis of DED, this article systematically compares the therapeutic targets, clinical evidence, and safety profiles of three representative topical immunomodulators: cyclosporine A, lifitegrast, and tacrolimus. By blocking T-cell activation and proliferation at various stages, these agents interrupt the self-amplifying inflammatory loop and have become core regimens for the long-term management of moderate-to-severe DED. After analyzing the limitations of existing research, the article highlights the need for future head-to-head clinical trials and the identification of predictive biomarkers to bridge current evidence gaps and guide the rational clinical selection of medications.
[中图分类号]
[基金项目]
秦创原中医药产业创新聚集区项目(No.L2024-QCY-ZYYJJQ-315)